An Open Labeled, Noncomparative, Phase I Study to Evaluate the Safety and tolerability of a Fully Liquid Hexavalent DTwP-HepB-Hib-IPV Vaccine (Easysix, Panacea Biotec Ltd.) in Healthy Subjects 15 - 18 months of age.

Trial Profile

An Open Labeled, Noncomparative, Phase I Study to Evaluate the Safety and tolerability of a Fully Liquid Hexavalent DTwP-HepB-Hib-IPV Vaccine (Easysix, Panacea Biotec Ltd.) in Healthy Subjects 15 - 18 months of age.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Hib-DTP-hepatitis B-poliovirus vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 23 Dec 2010 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India record.
    • 20 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top